Cargando…

Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization

BACKGROUND: The licensed smallpox vaccine, comprised of infectious vaccinia virus, has associated adverse effects, particularly for immunocompromised individuals. Therefore, safer DNA and protein vaccines are being investigated. The L1 protein, a component of the mature virion membrane that is conse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shinoda, Kaori, Wyatt, Linda S, Irvine, Kari R, Moss, Bernard
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654435/ https://www.ncbi.nlm.nih.gov/pubmed/19257896 http://dx.doi.org/10.1186/1743-422X-6-28

Ejemplares similares

Functional epitopes and neutralizing antibodies of vaccinia virus
por: Peng, Fenghao, et al.
Publicado: (2023)

Rapid detection of anti-Vaccinia virus neutralizing antibodies
por: Kramski, Marit, et al.
Publicado: (2011)

SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus
por: Kitabatake, Masahiro, et al.
Publicado: (2007)

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins
por: Wyatt, Linda S., et al.
Publicado: (2017)

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge
por: Nigam, Pragati, et al.
Publicado: (2007)

Evaluation of Monkeypox- and Vaccinia virus-neutralizing antibodies in human serum samples after vaccination and natural infection
por: Manenti, Alessandro, et al.
Publicado: (2023)

Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells
por: Peng, Chen, et al.
Publicado: (2020)

Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies
por: Lee, Namhee, et al.
Publicado: (2023)

Characterization of the immune response elicited by the vaccinia virus L3 protein delivered as naked DNA
por: Ramírez, Maite, et al.
Publicado: (2018)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

New p35 (H3L) Epitope Involved in Vaccinia Virus Neutralization and Its Deimmunization
por: Khlusevich, Yana, et al.
Publicado: (2022)

Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody
por: Cao, Xiaoling, et al.
Publicado: (2022)

Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus
por: van Diepen, Michiel T., et al.
Publicado: (2019)

Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk
por: Castilla, Joaquin, et al.
Publicado: (1998)

Passive Immunity to Vaccinia in Newborns: I. Placental Transmission of Antibodies
por: Kempe, C. Henry
Publicado: (1952)

A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma
por: Yoo, So Young, et al.
Publicado: (2019)

LYMPH NODES AS A SOURCE OF NEUTRALIZING PRINCIPLE FOR VACCINIA
por: McMaster, Philip D., et al.
Publicado: (1937)

DNA Vaccine–Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination
por: Hu, Xintao, et al.
Publicado: (2018)

SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells
por: Liu, Ruikang, et al.
Publicado: (2019)

Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen
por: Walper, Scott A., et al.
Publicado: (2014)

Effects of vaccinia virus uracil DNA glycosylase catalytic site and deoxyuridine triphosphatase deletion mutations individually and together on replication in active and quiescent cells and pathogenesis in mice
por: De Silva, Frank S, et al.
Publicado: (2008)

Toxic Factor(s) in Vaccinia Virus and Its Neutralization by Penicillin. A Preliminary Communication
por: Murthy, V. N. Krishna
Publicado: (1950)

Early Pro-Inflammatory Signal and T-Cell Activation Associate With Vaccine-Induced Anti-Vaccinia Protective Neutralizing Antibodies
por: Hou, Jue, et al.
Publicado: (2021)

Broad dengue neutralization in mosquitoes expressing an engineered antibody
por: Buchman, Anna, et al.
Publicado: (2020)

Design and Engineering of Deimmunized Vaccinia Viral Vectors
por: Song, Kevin, et al.
Publicado: (2020)

Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization
por: Noy-Porat, Tal, et al.
Publicado: (2023)

Vaccinia Virus Activation and Antagonism of Cytosolic DNA Sensing
por: El-Jesr, Misbah, et al.
Publicado: (2020)

P19-52 LB. Assessing and restructuring foreign gene insertion sites for enhanced stability of modified Vaccinia virus ankara recombinants expressing HIV genes
por: Wyatt, L, et al.
Publicado: (2009)

Mucosal Immunization Induces a Higher Level of Lasting Neutralizing Antibody Response in Mice by a Replication-Competent Smallpox Vaccine: Vaccinia Tiantan Strain
por: Lu, Bin, et al.
Publicado: (2011)

Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization
por: Hogan, Michael J., et al.
Publicado: (2018)

Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma
por: Yoo, So Young, et al.
Publicado: (2017)

Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes
por: Lou, Jiaying, et al.
Publicado: (2021)

A Novel High-Throughput Vaccinia Virus Neutralization Assay and Preexisting Immunity in Populations from Different Geographic Regions in China
por: Liu, Qiang, et al.
Publicado: (2012)

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
por: Kwa, S, et al.
Publicado: (2012)

Drosophila S2 Cells Are Non-Permissive for Vaccinia Virus DNA Replication Following Entry via Low pH-Dependent Endocytosis and Early Transcription
por: Bengali, Zain, et al.
Publicado: (2011)

Immunization of mice with vaccinia virus Tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus
por: Yang, Lei, et al.
Publicado: (2022)

The Membrane Fusion Step of Vaccinia Virus Entry Is Cooperatively Mediated by Multiple Viral Proteins and Host Cell Components
por: Laliberte, Jason P., et al.
Publicado: (2011)

Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins
por: Gangadhara, Sailaja, et al.
Publicado: (2017)

Correction: Broad dengue neutralization in mosquitoes expressing an engineered antibody
por: Buchman, Anna, et al.
Publicado: (2020)

Origin-independent plasmid replication occurs in vaccinia virus cytoplasmic factories and requires all five known poxvirus replication factors
por: De Silva, Frank S, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_naa6jihduhu3tk747tsuud9h8f